OR WAIT null SECS
Mike Hennessy Jr. is the President and CEO of MJH Life Sciences.
July 03, 2024
A greater number of patients with Duchenne muscular dystrophy will be able to be treated after FDA's approval of a gene therapy.
June 03, 2024
Improved efficiencies and reduced costs are clear advantages of automating drug manufacturing processes.
May 03, 2024
Technological advances are helping advance biologics development and manufacturing and reduce bottlenecks.
April 02, 2024
Experts believe it is likely cancer cells are more common in the body than previously thought, but typically caught early and removed in the body’s cancer-immune cycle. When the system is in good working order (and protecting us), dead cancer cells release neoantigens.
March 02, 2024
While Catalent’s acquisition is definitely about making drugs, it’s also very much about making money.
February 02, 2024
Given its positioning at each new year’s commencement, the J.P. Morgan Healthcare conference helps establish the tone with which the pharmaceutical industry is viewed.